A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Registration Number
- NCT00069121
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This 2 arm study will compare the efficacy and safety of intermittent oral Xeloda plus Eloxatin (oxaliplatin) with that of fluorouracil/leucovorin in patients who have had surgery for colon cancer and no previous chemotherapy. Patients will be randomized to receive either 1) XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or 2)5-fluorouracil + leucovorin in 4 or 8 week cycles. The anticipated time on study treatment is until disease progression and the target sample size is 500+ individuals.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1886
- Histologically confirmed colon carcinoma, AJCC/UICC Stage III (Dukes stage C)
- Complete tumor resection; Patients operated with curative intent and with no macroscopic or microscopic evidence for remaining tumor who can be randomized to either treatment arm within 8 weeks after surgery. As this is an adjuvant trial patients should never have had any evidence of metastatic disease (including presence of tumor cells in the ascites).
- Have a life expectancy of at least 5 years
- Pregnant or lactating women
- Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study
- Previous cytotoxic chemotherapy, radiotherapy or immunotherapy, for the currently treated colon cancer
- Patients who have not completely recovered from surgery
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 5-Fluorouracil/Leucovorin (5-FU/LV) Leucovorin (LV) Participants were given one of two regimens (each participating center prespecified which regimen they would use for all patients at that center): i) Mayo Clinic regimen group: LV 20 mg/m\^2 IV bolus injection + 5-FU 425 mg/m\^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or; ii) Roswell Park regimen group: LV 500 mg/m\^2 by two-hour IV infusion + 5-FU 500 mg/m\^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks). 5-Fluorouracil/Leucovorin (5-FU/LV) 5-Fluorouracil (5-FU) Participants were given one of two regimens (each participating center prespecified which regimen they would use for all patients at that center): i) Mayo Clinic regimen group: LV 20 mg/m\^2 IV bolus injection + 5-FU 425 mg/m\^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or; ii) Roswell Park regimen group: LV 500 mg/m\^2 by two-hour IV infusion + 5-FU 500 mg/m\^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks). Capecitabine in Combination with Oxaliplatin (XELOX) Capecitabine Capecitabine was administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m\^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks). Capecitabine in Combination with Oxaliplatin (XELOX) Oxaliplatin Capecitabine was administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m\^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks).
- Primary Outcome Measures
Name Time Method Disease-Free Survival (DFS) [Time to Event] Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months). Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.
Disease-Free Survival (DFS) [Number of Events] Time from randomization date to date of first DFS event/date last known to be event-free. Median observation time for DFS was 74 months (range: 0-95 months). Determination of an event was based on tumor assessments and survival follow-up assessments. A disease-free survival (DFS) event was defined as any recurrence of the original colon cancer or appearance of a new colon or rectal cancer (proven by cytology or histology, when possible) or death due to any cause, whichever was earliest. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants with no tumor assessments after baseline were censored at Day 1. An isolated event of increased CEA, or unexplained clinical deterioration were not considered to be evidence of relapse without support of other objective measurements. The date of relapse was defined as the date of the definitive assessment by objective measurements.
- Secondary Outcome Measures
Name Time Method Relapse-Free Survival (RFS) [Number of Events] Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months). A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment.
Relapse-Free Survival (RFS) [Time to Event] Time from randomization date to date of first RFS event/date last known to be event-free. Median observation time for RFS was 74 months (range: 0-95 months). A relapse-free survival (RFS) event included recurrence of the original colon cancer, development of a new colon or rectal cancer, and deaths related to any of the following: treatment, recurrence of the original colon cancer, or development of a new colon or rectal cancer. Participants who had not had any such event at the time of data analysis were censored at the last date they were known to be event-free. Participants whose cause of death was unrelated to treatment or disease recurrence were censored at the time of the last tumor assessment. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.
Overall Survival [Time to Event] Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months). Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive. The median was estimated by the Kaplan-Meier method. The full range values include censored observations.
Overall Survival [Number of Events] Time from randomization date to date of death/date last known to be alive. Median observation time was 83 months (range: 0-95 months). Overall survival was measured as the time from randomization to the date of death, irrespective of the cause of death. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive.
Number of Participants With at Least One Adverse Event by Most Severe Intensity From time of very first drug intake to 28 days after very last drug intake (median [full range] duration of study treatment per arm: 5-FU/LV MAYO CLINIC: 145 [4-208] days; 5-FU/LV ROSWELL PARK: 204 [1-239] days; XELOX: 163 [1-275] days). The intensity of all adverse events (AEs) was categorized according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) (version 3.0) grading system. If an AE had occurred which was not contained in the NCI-CTC, a four-point scale (mild, moderate, severe, life-threatening) was used. The terms "severe" and "serious" are not synonymous and are independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of an AE in one individual. See the AEs results table for details.
Trial Locations
- Locations (232)
New Mexico Oncology Hematology Consultants
🇺🇸Albuquerque, New Mexico, United States
Innovative clinical research institute/American institute of research
🇺🇸Whittier, California, United States
Nh Oncology Hematology, Pa
🇺🇸Hooksett, New Hampshire, United States
Wilshire Oncology Medical Group
🇺🇸Pomona, California, United States
Central Hematology Oncology Medical Group Inc.
🇺🇸Alhambra, California, United States
St. Vincent'S Hospital; Comprehensive Care Center
🇺🇸New York, New York, United States
Lakeland Regional Cancer Center
🇺🇸Lakeland, Florida, United States
Illinois Cancer Care
🇺🇸Peoria, Illinois, United States
Morristown Medical Center;Hematology-Oncology Assoc
🇺🇸Morristown, New Jersey, United States
San Diego Cancer Center'S Medical Group
🇺🇸Vista, California, United States
Ochsner Cancer Inst.
🇺🇸New Orleans, Louisiana, United States
Hope Center
🇺🇸Terre Haute, Indiana, United States
Footscray Hospital
🇦🇺Footscray, Victoria, Australia
Dr. H. Bliss Murphy Cancer Centre; Oncology
🇨🇦St. John's, Newfoundland and Labrador, Canada
The Ottawa Hospital Cancer Centre; Oncology
🇨🇦Ottawa, Ontario, Canada
Cancer Hospital Chinese Academy of Medical Sciences.
🇨🇳Beijing, China
Aberdeen Royal Infirmary; Medical Oncology Dept
🇬🇧Aberdeen, United Kingdom
Derbyshire Royal Infirmary; Dept of Oncology
🇬🇧Derby, United Kingdom
St James Institute of Oncology
🇬🇧Leeds, United Kingdom
Leicester Royal Infirmary; Dept. of Medical Oncology
🇬🇧Leicester, United Kingdom
Nottingham City Hospital; Oncology
🇬🇧Nottingham, United Kingdom
Derriford Hospital; Plymouth Oncology Centre
🇬🇧Plymouth, United Kingdom
Salisbury District General Hospital; Medical Oncology Dept
🇬🇧Salisbury, United Kingdom
Addenbrooke'S Hospital; Univ.Dept.& Mrc Unit of Clin.Oncology & Radiotherapeutics
🇬🇧Cambridge, United Kingdom
Cruk Clinical Trials Unit; Level 0 Beatson West Of Scotland Cancer Ctr
🇬🇧Glasgow, United Kingdom
Charing Cross Hospital; Medical Oncology.
🇬🇧London, United Kingdom
Royal Marsden Nhs Trust; Consultant Cancer Physician
🇬🇧London, United Kingdom
The Royal Sussex County Hospital; the Sussex Cancer Centre
🇬🇧Brighton, United Kingdom
Hammersmith Hospital; Mrc Clinical Science Centre
🇬🇧London, United Kingdom
West Suffolk Hospital Nhs Trust; Gi Corridor
🇬🇧Bury St Edmunds, United Kingdom
Maidstone Hospital
🇬🇧Maidstone, United Kingdom
James Cook Uni Hospital
🇬🇧Middlesborough, United Kingdom
Southampton General Hospital; Somers Cancer Research Building
🇬🇧Southampton, United Kingdom
Royal Marsden Hospital; Dept of Medical Oncology
🇬🇧Sutton, United Kingdom
Comprehensive Blood/Cancer Ctr
🇺🇸Bakersfield, California, United States
Virginia K. Crossen Cancer Center
🇺🇸Fullerton, California, United States
Santa Barbara Hematology Oncology Medical Group, Inc.
🇺🇸Santa Barbara, California, United States
Hematology Oncology P.C.
🇺🇸Stamford, Connecticut, United States
US Oncology
🇺🇸The Woodlands, Texas, United States
St Joseph Oncology
🇺🇸Saint Joseph, Missouri, United States
Moses Cone Reg Cancer Ctr
🇺🇸Greensboro, North Carolina, United States
Royal Prince Alfred Hospital; Medical Oncology
🇦🇺Camperdown, New South Wales, Australia
Medical Oncology Associates
🇺🇸Kingston, Pennsylvania, United States
Hospital of the Uni of Pennsylvania; Section of Hematology/Oncology
🇺🇸Philadelphia, Pennsylvania, United States
Uni of Miami School of Medicine; Sylvester Comprehensive Cancer Center
🇺🇸Miami, Florida, United States
The 1st Affiliated Hospital of Nanchang Unversity
🇨🇳Nanchang, China
Jiangsu Cancer Hospital
🇨🇳Nanjing, China
Shandong Cancer Hospital; Oncology
🇨🇳Shandong, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai City, China
Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)
🇨🇳Shanghai, China
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
🇨🇳Wuhan, China
St John of God Hospital; Medical Oncology
🇦🇺Perth, Western Australia, Australia
The Cancer Center At Providence Park
🇺🇸Mobile, Alabama, United States
Pacific Shores Medical Group
🇺🇸Long Beach, California, United States
West Valley Hematology Oncology The Thomas and Dorothy Leavey Cancer Center
🇺🇸Northridge, California, United States
Ventura County Hematology-Oncology Specialists
🇺🇸Oxnard, California, United States
Georgetown Uni Medical Center; Lombardi Cancer Center
🇺🇸Washington, District of Columbia, United States
Fox Chase-Temple Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
West Clinic
🇺🇸Germantown, Tennessee, United States
Uni of Pittsburgh Cancer Inst. ; Oncology
🇺🇸Pittsburgh, Pennsylvania, United States
Port Macquarie Base Hospital; Oncology
🇦🇺Port Macquarie, New South Wales, Australia
Southern Medical Day Care; Clinical Trials Unit
🇦🇺Wollongong, New South Wales, Australia
Queen Elizabeth Hospital; Medical Oncology
🇦🇺Woodville South, South Australia, Australia
AZ Groeninge
🇧🇪Kortrijk, Belgium
Hospital de Baleia; Serviço de Oncologia Clínica
🇧🇷Belo Horizonte, MG, Brazil
Hospital das Clinicas - FMUSP; Gastroenterologia
🇧🇷Sao Paulo, SP, Brazil
Tom Baker Cancer Centre; Dept of Medicine
🇨🇦Calgary, Alberta, Canada
Cross Cancer Institute ; Dept of Medical Oncology
🇨🇦Edmonton, Alberta, Canada
Bcca - Cancer Center Southern Interior
🇨🇦Kelowna, British Columbia, Canada
Bcca - Vancouver Island Cancer Centre; Oncology
🇨🇦Victoria, British Columbia, Canada
St. Boniface General Hospital
🇨🇦Winnipeg, Manitoba, Canada
Queen Elizabeth II Health Sciences Centre; Oncology
🇨🇦Halifax, Nova Scotia, Canada
Hamilton Health Sciences - Juravinski Cancer Centre
🇨🇦Hamilton, Ontario, Canada
London Regional Cancer Centre
🇨🇦London, Ontario, Canada
Credit Valley Hospital/Carlo Fidani Peel Regional Cancer Centre
🇨🇦Mississauga, Ontario, Canada
Lakeridge Health Oshawa; Oncology
🇨🇦Oshawa, Ontario, Canada
Humber River Hospital
🇨🇦Toronto, Ontario, Canada
Sunnybrook Health Science Centre
🇨🇦Toronto, Ontario, Canada
Cite de La Sante de Laval; Hemato-Oncologie
🇨🇦Laval, Quebec, Canada
Hotel Dieu de Levis; Oncology
🇨🇦Levis, Quebec, Canada
Hopital Maisonneuve- Rosemont; Oncology
🇨🇦Montreal, Quebec, Canada
Chum Campus Notre Dame
🇨🇦Montreal, Quebec, Canada
Hopital Du Sacre Coeur de Montreal; Pneumologie
🇨🇦Montreal, Quebec, Canada
Nanfang Hospital, Southern Medical University
🇨🇳Guangzhou, China
Chuq - Hopital Hotel Dieu de Quebec; Oncology
🇨🇦Quebec City, Quebec, Canada
The Second Affiliated Hospital of Zhejiang University College
🇨🇳Hangzhou, China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
🇨🇳Shanghai, China
Tianjin Cancer Hospital
🇨🇳Tianjin, China
Turku Uni Central Hospital; Oncology Clinics
🇫🇮Turku, Finland
Hopital Louis Pasteur; Medecine B
🇫🇷Colmar, France
Institut Paoli Calmettes; Oncologie Medicale
🇫🇷Marseille, France
Hopital Civil; Hematologie Oncologie
🇫🇷Strasbourg, France
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
🇩🇪Freiburg, Germany
Universitaetsklinikum Halle; Klinik u.Poliklinik fuer Innere Medizin IV
🇩🇪Halle, Germany
Klinikum Magdeburg gemeinnützige GmbH; Klinik Haematologie und Onkologie
🇩🇪Magdeburg, Germany
Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie
🇩🇪Trier, Germany
Evangelismos Hospital; Medical Oncology
🇬🇷Athens, Greece
Theageneio Anticancer Hospital; Gastroenterology
🇬🇷Thessaloniki, Greece
Queen Mary Hospital; Surgery
🇭🇰Hong Kong, Hong Kong
Fovarosi Szent Laszlo Korhaz-Rendelointezet; Onkologiai Osztaly X
🇭🇺Budapest, Hungary
Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
🇭🇺Szeged, Hungary
Orszagos Onkologial Intezet; Onkologiai Osztaly X
🇭🇺Budapest, Hungary
St. James Hospital; Oncology
🇮🇪Dublin, Ireland
Hadassah Ein Karem Hospital; Oncology Dept
🇮🇱Jerusalem, Israel
Chaim Sheba Medical Center; Oncology Dept
🇮🇱Ramat Gan, Israel
Sourasky / Ichilov Hospital; Oncology Department
🇮🇱Tel Aviv, Israel
Assaf Harofeh; Oncology
🇮🇱Zerifin, Israel
Ospedale Cervesi di Cattolica; ONCOLOGIA
🇮🇹Cattolica, Emilia-Romagna, Italy
Ospedale Regionale Di Parma; Divisione Di Oncologia Medica
🇮🇹Parma, Emilia-Romagna, Italy
Ospedale Degli Infermi; Divisione Di Oncologia
🇮🇹Rimini, Emilia-Romagna, Italy
Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia
🇮🇹Udine, Friuli-Venezia Giulia, Italy
Asst Papa Giovanni XXIII; Oncologia Medica
🇮🇹Bergamo, Lombardia, Italy
A.O.U. Ospedali Riuniti Umberto I-G.M.Lancisi-G.Salesi Ancona;S.O.D. MED.Interna-Clinica Oncologica
🇮🇹Ancona, Marche, Italy
Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica
🇮🇹Milano, Lombardia, Italy
Ospedale Civile; Oncologia Medica
🇮🇹Sassari, Sardegna, Italy
Azienda Usl 7; Dept. Oncologico
🇮🇹Poggibonsi, Toscana, Italy
Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology
🇰🇷Seoul, Korea, Republic of
Yonsei Medical Center; Dept. of Medicine , Division of Hemato-Oncology
🇰🇷Seoul, Korea, Republic of
Hanyang Uni Hospital; Dept. of Internal Medicine , Section of Hemato-Oncology
🇰🇷Seoul, Korea, Republic of
Samsung Medical Centre; Division of Hematology/Oncology
🇰🇷Seoul, Korea, Republic of
Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology
🇰🇷Seoul, Korea, Republic of
Auckland city hospital; Auckland Regional Cancer Centre and Blood Service
🇳🇿Auckland, New Zealand
Dunedin Hospital; Oncology - Haematology Clinical Practice Group
🇳🇿Dunedin, New Zealand
Christchurch Hospital; Dept of Oncology
🇳🇿Christchurch, New Zealand
Palmerston North Hospital; Regional Cancer Treatment Service
🇳🇿Palmerston North, New Zealand
Wellington Hospital; Regional Oncology Unit
🇳🇿Wellington, New Zealand
Rydygiera Hospital; Chemotherapy
🇵🇱Krakow, Poland
Wielkopolskie Centrum Onkologii; Oddzial Chemioterapii
🇵🇱Poznan, Poland
Lubuski Osrodek Onkologii, Szpital Wojewodzki; Oddzial Onkologii
🇵🇱Zielona Gora, Poland
Hospital Jose Joaquim Fernandes; Unidade de Oncologia Medica
🇵🇹Beja, Portugal
Hospital de Santa Maria; Servico de Oncologia Medica
🇵🇹Lisboa, Portugal
IPO do Porto; Servico de Oncologia Medica
🇵🇹Porto, Portugal
Petrov Research Inst. of Oncology; Dept of Bio-Therapy & Transplantation of Bone Marrow
🇷🇺St Petersburg, Russian Federation
National Cancer Centre; Medical Oncology
🇸🇬Singapore, Singapore
National University Hospital; National University Cancer Institute, Singapore (NCIS)
🇸🇬Singapore, Singapore
Panorama Medical Clinic; Oncology Unit
🇿🇦Cape Town, South Africa
Hopelands Cancer Centre; Oncology
🇿🇦Durban, South Africa
Hopelands Cancer Centre ST. ANNES HOSPITAL; DEPT. OF ONCOLOGY
🇿🇦Pietermaritzburg, South Africa
Sandton Oncology Medical Group
🇿🇦Sandton, South Africa
Hospital Universitario Marques de Valdecilla; Servicio de Oncologia
🇪🇸Santander, Cantabria, Spain
Hospital Universitario Reina Sofia; Servicio de Oncologia
🇪🇸Córdoba, Cordoba, Spain
Hospital Universitario Puerta de Hierro; Servicio de Oncologia
🇪🇸Majadahonda, Madrid, Spain
Hospital Univ Vall d'Hebron; Servicio de Oncologia
🇪🇸Barcelona, Spain
Hospital de Cruces; Servicio de Oncologia
🇪🇸Bilbao, Vizcaya, Spain
Hospital Clínic i Provincial; Servicio de Hematología y Oncología
🇪🇸Barcelona, Spain
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia
🇪🇸Jaen, Spain
Hospital Universitario de la Princesa; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario Clínico San Carlos; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario La Paz; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Regional Universitario Carlos Haya; Servicio de Oncologia
🇪🇸Malaga, Spain
Instituto Valenciano Oncologia; Oncologia Medica
🇪🇸Valencia, Spain
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
🇪🇸Valencia, Spain
Hospital Universitario la Fe; Servicio de Oncologia
🇪🇸Valencia, Spain
Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology
🇨🇳Taipei City, Taiwan
Mackay Memorial Hospital; Department of Surgery, Division of Colon and Rectal Surgery
🇨🇳Taipei, Taiwan
Chang Gung Medical Foundation - Linkou; Colo-rectal Surgery
🇨🇳Taoyuan, Taiwan
Bumrungrad Hospital Foundation; Horizon Centre
🇹🇭Bangkok, Thailand
Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
🇹🇭Bangkok, Thailand
Srinagarind Hospital; Medical Oncology Unit
🇹🇭Khon Kaen, Thailand
Va Medical Center
🇺🇸Reno, Nevada, United States
Tampere University Hospital; Dept of Oncology
🇫🇮Tampere, Finland
University Hospital of Patras Medical Oncology
🇬🇷Patras, Greece
Shaare Zedek Medical Center; Oncology Dept
🇮🇱Jerusalem, Israel
Hematology-Oncology Centers of the Northern Rockies
🇺🇸Billings, Montana, United States
Bcca-Fraser Valley Cancer Centre
🇨🇦Surrey, British Columbia, Canada
Great Falls Clinic
🇺🇸Great Falls, Montana, United States
Cliniques Universitaires St-Luc
🇧🇪Bruxelles, Belgium
GHdC Site Notre Dame
🇧🇪Charleroi, Belgium
Box Hill Hospital; Oncology
🇦🇺Box Hill, Victoria, Australia
UZ Gent
🇧🇪Gent, Belgium
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium
Galway Uni Hospital; Oncology Dept
🇮🇪Galway, Ireland
Meir Medical Center; Oncology
🇮🇱Kfar-Saba, Israel
Univ General Hosp Heraklion; Medical Oncology
🇬🇷Heraklion, Greece
Per. Gen. Hospital Ippokrateion; Oncology Dept.
🇬🇷Athens, Greece
Ogyi, Orszagos Gyogyszereszeti Intezet
🇭🇺Budapest, Hungary
Mercy Uni Hospital; Deparment of Medical Oncology
🇮🇪Cork, Ireland
Theagenio Anticancer Hospital; 3Rd Oncology Clinic
🇬🇷Thessaloniki, Greece
Soroka Medical Center; Oncology Dept
🇮🇱Beer Sheva, Israel
Centro Estatal de Cancerología
🇲🇽Chihuahua, Mexico
Az. Osp. Uni Ria San Martino; Cliniche Uni Rie Convenzionate U.O. Oncologia Medical
🇮🇹Genova, Liguria, Italy
Rambam Medical Center; Oncology
🇮🇱Haifa, Israel
Hospital Christus Muguerza Del Parque; Centro de Rehabilitacion
🇲🇽Chihuahua, Mexico
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
🇹🇭Bangkok, Thailand
Blokhin Cancer Research Center; Combined Treatment
🇷🇺Moscow, Russian Federation
Nahariya Hospital; Oncology
🇮🇱Nahariya, Israel
Rabin Medical Center; Oncology Dept
🇮🇱Petach Tikva, Israel
Golda Hasharon Medical Center; Oncology
🇮🇱Petach Tikva, Israel
Clinica de Especialidades # 30 Dr. Humberto Torres Sangines; Oncology
🇲🇽Mexicali, Mexico
Kaplan Medical Center; Oncology Inst.
🇮🇱Rehovot, Israel
Instituto Nacional De Ciencias Medicas Y Nutricion; Nefrology
🇲🇽Mexico City, Mexico
Isthmian Medical Research Center, S.A.; Oncology
🇵🇦Panama City, Panama
Wojewodzki Szpital Specjalistyczny Im. M. Kopernika; Oddzial Chorob Rozrostowych
🇵🇱Lodz, Poland
Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Klinika Nowotworow Jelita Grubego
🇵🇱Warszawa, Poland
Hospital General Universitario de Elche; Servicio de Oncologia
🇪🇸Elche, Alicante, Spain
Pramongkutklao Hospital; Medicine - Medical Oncology Unit
🇹🇭Bangkok, Thailand
Zachodniopomorskie Centrum Onkologii, Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych
🇵🇱Szczecin, Poland
N.N.Burdenko Main Military Clinical Hospital; Chemotherapy
🇷🇺Moscow, Russian Federation
St. Petersburg City Clinical Oncological Dispensary; Colorectal (Department 4)
🇷🇺St Petersburg, Russian Federation
Hospital Universitario Son Espases
🇪🇸Palma De Mallorca, Islas Baleares, Spain
Universitaetsspital Basel; Onkologie
🇨🇭Basel, Switzerland
Ospedale Civile; Unita Operativa Di Oncologia Medica
🇮🇹Livorno, Toscana, Italy
Hopital Claude Huriez; Medecine Interne Oncologie
🇫🇷Lille, France
St Thomas Hospital; Oncology Dept
🇬🇧London, United Kingdom
Royal Surrey County Hospital; St. Lukes Cancer Centre
🇬🇧Guildford, United Kingdom
Christie Hospital; Breast Cancer Research Office
🇬🇧Manchester, United Kingdom
Northern Centre for Cancer Care;Oncology
🇬🇧Newcastle Upon Tyne, United Kingdom
Mount Vernon Hospital; Centre For Cancer Treatment
🇬🇧Northwood, United Kingdom
North Wales Cancer Treatment Centre, Glan Clwyd Hospital
🇬🇧Rhyl, United Kingdom
University Health Network; Princess Margaret Hospital; Medical Oncology Dept
🇨🇦Toronto, Ontario, Canada
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
🇨🇦Montreal, Quebec, Canada
Hospital Amaral Carvalho
🇧🇷Jau, SP, Brazil
Little Company of Mary Hospital; Mary Potter Oncology Centre
🇿🇦Pretoria, South Africa
Hematology Oncology Consultants, Inc.
🇺🇸Saint Louis, Missouri, United States
Hospital Severo Ochoa; Servicio de Oncologia
🇪🇸Leganes, Madrid, Spain
Hospital Duran i Reynals; Oncologia
🇪🇸Barcelona, Spain
Georgia Cancer Specialists
🇺🇸Atlanta, Georgia, United States
Sutter Cancer Center
🇺🇸Sacramento, California, United States
Kaiser Permanente San Diego; Hepatology Research
🇺🇸San Diego, California, United States
Scripps Cancer Center
🇺🇸San Diego, California, United States
University of Colorado Health Science Center; Biomedical Research Bldg. Room 511
🇺🇸Aurora, Colorado, United States
Intermountain Hematology & Oncology
🇺🇸Salt Lake City, Utah, United States
Internal Medicine Associates of Yakima Inc.
🇺🇸Yakima, Washington, United States
Park Nicollet Clinic Cancer Center
🇺🇸Saint Louis Park, Minnesota, United States
UNI OF WISCONSIN SCHOOL OF MEDICINE; GI Oncology Research Group, Paul P Carbone Cancer Center
🇺🇸Madison, Wisconsin, United States
Hematology Oncology Associates
🇺🇸Fort Collins, Colorado, United States
Oncology-Hematology of Lehigh Valley, Pc
🇺🇸Bethlehem, Pennsylvania, United States
Carolina Oncology Specialists, PA - Hickory
🇺🇸Hickory, North Carolina, United States
Presbyterian Healthcare; Cancer Research Dept
🇺🇸Charlotte, North Carolina, United States
Overlook Oncology Center; Summit Medical Group
🇺🇸Summit, New Jersey, United States